Development and Internal Validation of a Multivariable Prediction Model for Adrenocortical-Carcinoma-Specific Mortality.

adrenocortical carcinoma mortality prediction

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
22 Sep 2020
Historique:
received: 28 05 2020
revised: 09 08 2020
accepted: 11 09 2020
entrez: 25 9 2020
pubmed: 26 9 2020
medline: 26 9 2020
Statut: epublish

Résumé

Adrenocortical carcinoma (ACC) has an incidence of about 1.0 per million per year. In general, survival of patients with ACC is limited. Predicting survival outcome at time of diagnosis is a clinical challenge. The aim of this study was to develop and internally validate a clinical prediction model for ACC-specific mortality. Data for this retrospective cohort study were obtained from the nine centers of the Dutch Adrenal Network (DAN). Patients who presented with ACC between 1 January 2004 and 31 October 2013 were included. We used multivariable Cox proportional hazards regression to compute the coefficients for the prediction model. Backward stepwise elimination was performed to derive a more parsimonious model. The performance of the initial prediction model was quantified by measures of model fit, discriminative ability, and calibration. We undertook an internal validation step to counteract the possible overfitting of our model. A total of 160 patients were included in the cohort. The median survival time was 35 months, and interquartile range (IQR) 50.7 months. The multivariable modeling yielded a prediction model that included age, modified European Network for the Study of Adrenal Tumors (mENSAT) stage, and radical resection. The c-statistic was 0.77 (95% Confidence Interval: 0.72, 0.81), indicating good predictive performance. We developed a clinical prediction model for ACC-specific mortality. ACC mortality can be estimated using a relatively simple clinical prediction model with good discriminative ability and calibration.

Identifiants

pubmed: 32971946
pii: cancers12092720
doi: 10.3390/cancers12092720
pmc: PMC7564668
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Am J Surg Pathol. 2016 Apr;40(4):569-76
pubmed: 26685085
J Clin Pathol. 2008 Jul;61(7):787-93
pubmed: 18430754
Cancer. 2008 Dec 1;113(11):3130-6
pubmed: 18973179
Eur J Cancer. 2013 Jul;49(11):2579-86
pubmed: 23561851
Clin Cancer Res. 2019 Jun 1;25(11):3276-3288
pubmed: 30770352
Am J Surg Pathol. 1984 Mar;8(3):163-9
pubmed: 6703192
Clin Endocrinol (Oxf). 2013 Oct;79(4):468-75
pubmed: 23444945
J Clin Oncol. 2010 Aug 10;28(23):e401-2; author reply e403
pubmed: 20567001
Cancer. 2009 Jan 15;115(2):243-50
pubmed: 19025987
Cancer Commun (Lond). 2019 Nov 27;39(1):80
pubmed: 31775884
Ann Surg Oncol. 2015 Jan;22(1):146-51
pubmed: 25092161
Nat Rev Clin Oncol. 2018 Jul;15(7):459-466
pubmed: 29666440
Eur J Endocrinol. 2001 Sep;145(3):335-41
pubmed: 11517015
J Clin Endocrinol Metab. 2015 Mar;100(3):841-9
pubmed: 25559399
Mod Pathol. 2003 Aug;16(8):742-51
pubmed: 12920217
Cancer Cell. 2016 May 9;29(5):723-736
pubmed: 27165744
Cancer Manag Res. 2018 Dec 13;10:6949-6959
pubmed: 30588100
Nat Genet. 2014 Jun;46(6):607-12
pubmed: 24747642
Eur J Endocrinol. 2013 Oct 23;169(6):891-899
pubmed: 24086089
Front Cell Dev Biol. 2015 Jul 03;3:45
pubmed: 26191527
J Clin Endocrinol Metab. 2013 Jan;98(1):E174-84
pubmed: 23093492
Endocr J. 2008 Mar;55(1):49-55
pubmed: 18187873
Cancers (Basel). 2020 May 13;12(5):
pubmed: 32414074
Eur J Endocrinol. 2012 Jan;166(1):61-7
pubmed: 22048964
Horm Cancer. 2016 Dec;7(5-6):336-344
pubmed: 27422613
BJU Int. 2009 Dec;104(11):1661-7
pubmed: 19493261
Ann Oncol. 2015 Oct;26(10):2119-25
pubmed: 26392430
J Clin Endocrinol Metab. 2017 Mar 1;102(3):923-932
pubmed: 27967600
Eur J Cancer. 2010 Mar;46(4):713-9
pubmed: 20044246
JAMA Surg. 2016 Apr;151(4):365-73
pubmed: 26676603
Eur J Endocrinol. 2008 Jun;158(6):911-9
pubmed: 18505909
World J Surg. 2006 May;30(5):872-8
pubmed: 16680602
J Clin Endocrinol Metab. 2007 Jan;92(1):148-54
pubmed: 17062775
Hum Pathol. 2009 Jun;40(6):757-68
pubmed: 19442788
Cancer. 1985 Feb 15;55(4):766-73
pubmed: 3967172
J Clin Oncol. 2009 Mar 1;27(7):1108-15
pubmed: 19139432

Auteurs

Madeleine H T Ettaieb (MHT)

Department of Internal Medicine, Division of Endocrinology, Máxima Medical Center, 5631 Eindhoven/Veldhoven, The Netherlands.

Sander M J van Kuijk (SMJ)

Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, 6229 Maastricht, The Netherlands.

Annelies de Wit-Pastoors (A)

Department of Internal Medicine, Division of Endocrinology, Máxima Medical Center, 5631 Eindhoven/Veldhoven, The Netherlands.

Richard A Feelders (RA)

Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, 2333 Leiden, The Netherlands.

Eleonora P M Corssmit (EPM)

Department of Internal Medicine, Division of Endocrinology, VU Medical Center, 1081 Amsterdam, The Netherlands.

Elisabeth M W Eekhoff (EMW)

Department of Pathology, Location VU Medical Center, Amsterdam University Medical Centers, 1081 Amsterdam, The Netherlands.

Paul van der Valk (P)

Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, 6525 Nijmegen, The Netherlands.

Henri J L M Timmers (HJLM)

Department of Endocrinology, University of Groningen, University Medical Center Groningen, 9713 Groningen, The Netherlands.

Michiel N Kerstens (MN)

Department of Medical Oncology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, 1105 Amsterdam, The Netherlands.

Heinz-Josef Klümpen (HJ)

Department of Endocrine Oncology, University Medical Center Utrecht, 3584 Utrecht, The Netherlands.

van Rachel S Leeuwaarde (VRS)

Department of Internal Medicine, Division of Endocrinology and Metabolism, Maastricht University Medical Center, 6229 Maastricht, The Netherlands.

Bas Havekes (B)

Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, 3015 Rotterdam, The Netherlands.

Harm R Haak (HR)

Department of Internal Medicine, Division of Endocrinology, Máxima Medical Center, 5631 Eindhoven/Veldhoven, The Netherlands.
Department of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Center, 6229 Maastricht, The Netherlands.
CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, 6229 Maastricht, The Netherlands.

Classifications MeSH